Evaluating Off-Target Effects of RNA-Based Therapeutics in Preclinical Models
RNA-based therapeutics, including siRNA, antisense oligonucleotides (ASOs), and mRNA vaccines, offer precise modulation of gene expression but also present unique challenges related to off-target effects. These unintended interactions can lead to toxicity, immune activation, or altered expression of non-target genes, complicating preclinical safety assessments.
In vitro screening using transcriptomic and proteomic profiling helps identify off-target gene modulation, but in vivo models remain crucial to capture systemic effects, tissue distribution, and immune responses. Animal studies often incorporate dose-escalation and multiple administration routes to evaluate the therapeutic window and monitor organ-specific toxicities.
Chemical modifications to RNA molecules, such as 2’-O-methylation or locked nucleic acids (LNAs), are employed to improve specificity and reduce immunogenicity. Delivery vehicles, including lipid nanoparticles and polymer-based carriers, further influence biodistribution and off-target interactions.
Immune-related adverse effects are a particular concern; innate immune sensors like Toll-like receptors can recognize exogenous RNA, triggering cytokine release and inflammation. Thus, preclinical immunotoxicity evaluations include cytokine profiling, complement activation assays, and histopathology of immune organs.
Evaluating off-target effects is essential for establishing safety margins and informing dose selection for clinical trials. Advanced bioinformatics, in vitro screening panels, and relevant animal models form an integrated approach to predict and mitigate off-target risks.